Sermorelin: the native signal, shortened

Start here

The body's own growth-hormone-releasing hormone is a chain of forty-four building blocks. Only the first twenty-nine of them are needed to work; the rest can be removed without losing activity at the receptor.

Sermorelin is that first twenty-nine, made in a laboratory and nothing more. No substitutions, no protective modifications, no albumin hook. Where CJC-1295 is the native message re-engineered to last for days, sermorelin is the native message copied faithfully — which means it also disappears about as fast as the real thing.

That makes it the natural reference point on this map. It is also the only compound here with a regulatory past rather than a regulatory problem: it was once an approved medicine for children who did not make enough growth hormone, and it left the market for commercial reasons rather than because it failed. Most of what is claimed for it today concerns adults, and that is where its own evidence gets thin.

What it is

Sermorelin acetate is an amidated synthetic 29-amino-acid peptide corresponding to the amino-terminal 1-29 fragment of endogenous 44-residue human growth-hormone-releasing hormone. It is the shortest fully bioactive fragment: it retains full activity at the GHRH receptor ^[1]. It is known in the literature as GHRH(1-29), GRF(1-29) and GRF(1-29)NH2.

Its regulatory history is the part most often reported wrongly. Sermorelin acetate held a US approval, under NDA 020443, for idiopathic growth-hormone deficiency and short stature in children. That product was withdrawn from the US market in 2008 for commercial reasons — not for safety and not for efficacy. Sermorelin is now supplied through compounding pharmacies and is treated as a Category 1 bulk drug substance under the FDA's interim Section 503A policy, with final guidance issued in January 2025. Category 1 means the agency does not intend enforcement action against its compounding.

That status should not be blurred with the position of the other GH-axis peptides reviewed by the Pharmacy Compounding Advisory Committee in October 2024, ipamorelin among them. Sermorelin's paperwork and ipamorelin's paperwork tell opposite stories, and a site that files them under one heading is not reading them.

One further distinction belongs here. Oral, sublingual and troche preparations sold as sermorelin are widely criticised in research-use communities as ineffective, because peptides are degraded in the gut and cross mucosa poorly — a criticism consistent with the very low intranasal bioavailability reported for GHRH(1-29).

How it works

Sermorelin binds GHRH receptors on anterior-pituitary somatotrophs and activates the adenylate cyclase / cAMP / PKA pathway, stimulating synthesis and pulsatile release of the body's own growth hormone. The receptor, the cascade and the downstream IGF-1 response are the same ones CJC-1295 engages; the class review in Nature Reviews Endocrinology covers the receptor signalling and the therapeutic landscape for the whole GHRH analog family ^[1].

The mechanistic argument made for it is architectural rather than pharmacological. Because it acts upstream on the pituitary instead of supplying growth hormone from outside, the physiologic feedback through somatostatin and IGF-1 stays intact and the natural pulsatile pattern of secretion is preserved. An editorial in Clinical Interventions in Aging argues on exactly that basis that sermorelin may be a more physiologic approach to adult-onset growth-hormone insufficiency than recombinant growth hormone ^[15]. It is an argument from mechanism, and it is presented in the literature as such — not as a demonstrated outcome advantage.

The same architecture sets the compound's limits. The axis is built to fire in bursts, and it defends that design: when GHRH(1-29) was given to children as a continuous, uninterrupted infusion, the growth-hormone response faded over a few months and one child's secretion was fully suppressed. Steady, around-the-clock exposure desensitises the pituitary, which is why GHRH peptides are studied as intermittent signals rather than constant ones — and it is the clearest evidence on this desk that more continuous stimulation is not more stimulation.

What the research shows

In children, it worked, and that is where its own controlled data are. In a multicentre trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth, with first-year height velocity rising from about 4.1 centimetres per year to roughly 7 to 8 centimetres per year, and without excessive IGF-1 generation ^[16]. That last clause is the mechanistically interesting one: growth accelerated while IGF-1 stayed inside physiologic bounds, which is the behaviour a feedback-preserving secretagogue is supposed to show.

In adults, the best data belong to a different molecule. The strongest randomised evidence usually cited in support of adult GHRH-analog use comes from a trial of tesamorelin (Egrifta), not sermorelin: 152 older adults, 66 of them with mild cognitive impairment, received 1 mg per day subcutaneously before bedtime for 20 weeks. The trial reported a favourable effect on cognition (P = 0.03), a 117% increase in IGF-1 that remained within the physiologic range, and a 7.4% reduction in percent body fat ^[13]. Tesamorelin is a full-length GHRH analog and a different compound; the result supports the class, and it is regularly quoted as though it supported sermorelin specifically. It does not.

The class verdict on aging is on the record and unflattering. An Annals of Internal Medicine editorial concluded that using growth-hormone secretagogues to prevent or treat the effects of aging is not yet justified by the evidence, and called it "not yet ready for prime time" ^[14]. Sermorelin is marketed for anti-aging, fat loss and general vitality more heavily than anything else on this desk, and no long-term trial has since answered that editorial.

Where the case for it is strongest. Not in outcome data but in physiology: an upstream, feedback-preserving, pulsatility-respecting stimulus with a genuine controlled efficacy result in a deficiency population ^[16] and an explicit mechanistic argument in the literature for preferring it to exogenous growth hormone in adult-onset insufficiency ^[15]. That is a coherent position. It is not the same claim as an anti-aging benefit, and the two are routinely merged.

Reported effects, cautions and safety

The following account is anecdotal, not clinical evidence: it summarises what people in research-use and telehealth communities report, without controls, verification or measurement, and no quantities are given. Deeper sleep with notably vivid dreams in the first weeks is the single most common reason people say they try it. More daytime energy and a sense of faster recovery are frequently described, usually credited to the sleep rather than to any stimulant-like effect. Gradual loss of body fat over months is a common goal and a commonly reported result; better muscle tone, skin quality and general well-being appear occasionally. A recurring and unusually consistent theme is that the effect is slow and subtle — a "slow burn" in which the first month can feel like nothing at all, with several accounts describing early disappointment followed by change in the second or third month. On the adverse side, injection-site redness, itching or swelling is very commonly reported and usually short-lived; headache, flushing, dizziness or mild nausea in the first week or two are frequent; puffiness in the ankles, hands or face, increased appetite and post-dose drowsiness are occasional; tingling in the hands and a rise in blood sugar in predisposed people are reported rarely.

The documented cautions:

• The long-term wellness case is unproven. Sermorelin is marketed for anti-aging, fat loss and vitality; large long-term trials supporting those uses do not exist, and the standing editorial judgement on the class is that the evidence does not yet justify the practice ^[14].
• Theoretical oncologic risk from sustained GH and IGF-1 elevation. GH and IGF-1 promote cell growth, so deliberately raising them over long periods carries a theoretical cancer concern that applies to any GH-axis intervention. Sermorelin's feedback-preserving mechanism may temper how far IGF-1 climbs — the pediatric trial found no excessive IGF-1 generation ^[16] — but long-term human data have not resolved the question.
• Glucose tolerance, particularly in older adults. GH opposes insulin, so raising it can nudge blood sugar upward in susceptible people; repeated dosing of a long-acting GHRH peptide has been linked to some impairment of glucose tolerance in elderly subjects. Age, prediabetes and metabolic syndrome are the conditions under which this matters most.
• Injection-site reactions and minor metabolic shifts are the most consistent findings across human studies of GHRH(1-29), together with transient changes such as a temporary rise in blood lipids that resolved. Mild and reversible, but evidence that the response is not confined to the intended target.
• The pituitary is not a single switch. In a study of short children, an intravenous dose of GHRH(1-29) produced small, short-lived rises in prolactin, LH and FSH. The effect was minor; the principle is not.
• Continuous exposure blunts the response — the desensitisation described above under mechanism, and the reason intermittent signalling is the studied pattern.
• Gray-market product quality. Much of the sermorelin sold outside the pharmacy supply chain comes from a largely unregulated market in which critical reviews report frequent mislabelling and contamination; the contents of a given vial are not knowable from its label.
• Prohibited in sport. GH secretagogues including GHRH analogs are banned by WADA, and dedicated detection methods exist.

Where it sits on the map

Sermorelin is the origin point of the GHRH-receptor position: the unmodified native fragment against which CJC-1295's four substitutions and albumin conjugation are the deliberate departure. Same receptor, same cascade, same downstream axis — and the opposite pharmacokinetic strategy, native clearance instead of engineered persistence.

It is also the compound on this desk whose evidence and whose marketing point in the most different directions. Its controlled efficacy data are in children with a deficiency ^[16]; its adult data are largely borrowed from a different molecule ^[13]; and its commercial presence is almost entirely adult wellness. Reading it precisely means keeping those three facts separate, which is what the rest of this site is for.